MAPT and Alzheimer disease: In another study using tau and amyloid PET, participants at Stage 2 [amyloid (+) and tau (+)] of preclinical AD (14) were more likely to receive a marginal/fail rating compared to participants at Stage 0 [amyloid (-) and tau (-)] or 1 [amyloid (+) and tau (-)] (11, 14).